Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland

Journal of Medical Economics

Volumn 16, Issue 9, 2013, Pages 1096-1105

  Einarson, Thomas R ^a   Pudas, Hanna ^b   Zilbershtein, Roman ^c   Jensen, Rasmus ^a   Vicente, Colin ^c   Piwko, Charles ^c   Hemels, Michiel E H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Janssen Cilag   (Finland)

^c PIVINA Consulting Inc   (Canada)

Author keywords

Cost effectiveness; Olanzapine pamoate; Paliperidone palmitate; Risperidone long acting injection; Schizophrenia

Indexed keywords

OLANZAPINE; PALIPERIDONE; RISPERIDONE;

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; EMERGENCY WARD; FINLAND; HEALTH CARE COST; HEALTH SERVICE; HOSPITALIZATION COST; HUMAN; LONG TERM CARE; MEDICATION COMPLIANCE; NORWAY; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; REMISSION; SCHIZOPHRENIA; SIMULATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DELAYED-ACTION PREPARATIONS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; FINLAND; HUMANS; ISOXAZOLES; MALE; MULTIVARIATE ANALYSIS; PALMITATES; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84882993684     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.823869     Document Type: Article

References (69)

1. Mental health: schizophrenia. http://www.who.int/mental-health/manage ment/schizophrenia/en/. Accessed October 10, 2011
2. The global burden of disease: 2004 update. Geneva: World Health Organisation, 2008
3. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schiz Bull 2004;30:279-93 (Pubitemid 38828535)
4. Karagianis J, Novick D, Pecanek J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009;63:1578-88
5. Perä lä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar disorders in a general population. Arch Gen Psychiatry 2007;64:19-28 (Pubitemid 46041735)
6. Juvonen H, Reunanen A, Haukka J, et al. Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Arch Gen Psychiatry 2007;64:894-9 (Pubitemid 47230613)
7. Arajä rvi R, Suvisaari J, Suokas J, et al. Prevalence and diagnosis of schizophrenia based on register, case record and interview data in an isolated Finnish birth cohort born 1940-1969. Soc Psychiatry Psychiatr Epidemiol 2005;40:808-16 (Pubitemid 41600192)
8. Teperi J, Porter ME, Vuorenkoski L, et al The Finnish health care system: a value-based perspective. Sitra Reports Helsinki: Edita Prima Ltd, 2009
9. OECD report criticises Finland for inefficient treatment of mental illness. Helsingin Sanomat. http://www.hs.fi/english/article/OECD\+report\+ criticises\+Finland\+for\+inefficient\+treatment\+of\+mental\+illness/11352 51638800. Accessed October 10, 2011
10. Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-7 (Pubitemid 46425751)
11. Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9 (Pubitemid 32996037)
12. Mö ller HJ. Novel antipsychotics and negative symptoms. Int Clin Psychopharmacol 1998;13(3 Suppl):S43-7
13. Kane J, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32 (Pubitemid 41070972)
14. Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry-Mental Health Policy and Economics, Venice, Italy, March 25-27, 2011
15. European Medicines Agency. Assessment report for Zypadhera. Doc. Ref EMEA/608654/2008. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Public-assessment-report/human/000890/WC500054428.pd. Procedure No. EMEA/H/C/000890, 1-63. 2008. Accessed August 8, 2011.
16. European Medicines Agency. Zypadhera-product monograph. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Infor mation/human/000890/WC500054429.pdf. 20-4-2010. Accessed August 8, 2011.
17. European Medicines Agency. Xeplion-opinion. http://www.ema.europa. eu/ema/index.jspcurlpages/medicines/human/medicines/002105/smops/Positive/ human-smop-000162.jsp&murlmenus/medicines/medicines.jsp & midWC0b01ac058001d127. Accessed October 10, 2011.
18. European Medicines Agency. Xeplion-product monograph. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002105/WC500103317.pdf. Accessed October 10, 2011
19. Detke H, Mcdonnell D, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine longacting injection, I: analysis of cases. BMC Psychiatry 2010;10:32
20. Devadason P. Practical limitations of prescribing olanzapine depot (Relprevv). Australas Psychiatry 2010;18:269.
21. Alphs L, Gopal S, Karcher K, et al. Are long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium sedation syndrome An assessment of safety databases. Curr Drug Saf 2011;6:43-5
22. Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatrica 2012 (In press). Article first published online: 11 JUL 2012 j DOI: 10.1111/j.1601-5215.2012.00670.x
23. European Medicines Agency. Risperdal Consta-product monograph. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Risperdal-Consta-30/WC500008170.pdf. Accessed October 10, 2011
24. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010;25:685-97
25. Fleischhacker W, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;22:1-12
26. Gopal S, Hough D, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, doubleblind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
27. Pandina GJ, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
28. Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-31
29. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidencebased trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
30. Pandina GJ, Lindenmayer J-P, Lull JM, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44
31. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schiz Res 2010;116:107-17
32. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone-analysis of long-term efficacy. J Psychopharmacol 2005;19:15-21 (Pubitemid 41392293)
33. Lee M-S, Ko Y-H, Lee S-H, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407 (Pubitemid 44355619)
34. Lindenmayer J-P, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17: 138-44 (Pubitemid 44779189)
35. Olivares J, Rodrigues-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
36. Kane J, Detke H, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
37. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69: 790-9 (Pubitemid 351838688)
38. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17 (Pubitemid 39574406)
39. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91-100 (Pubitemid 38916632)
40. Olivares J, Peuskens J, Pecanek J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
41. Ascher-Svanum H, Faries D, Zhu B, et al. Medication adherence and longterm functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
42. Weiden P, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91 (Pubitemid 39025215)
43. Morken G, Widen J, Gra°we R. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32.
44. Simonsen E, Friis S, Opjordsmoen S, et al. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand 2010;122:375-83
45. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9 (Pubitemid 29302789)
46. Ministry of Social Affairs and Health, Finland. Guidelines for preparing a health economic evaluation. Helsinki, 2009. http://www.ispor.org/PEguidelines/ source/GuidelinesinFinland-EnglishVersion.pdf. Accessed October 10, 2011
47. Finland inflation rate (Consumer prices). http://www.indexmundi.com/ finland/inflation-rate-(consumer-prices).html. Accessed October 10, 2011
48. SLD price. Suomen Lä ä keData Oy (Finland). Helsinki: IMS Health Oy. http://www.sld.fi/finland.html. Accessed October 10, 2011
49. Hujanen T, Kapienen S, Tuominen U, et al. Terveydenhuollon yksikkö kustannukset Suomessa vuonna 2006. Helsinki: Stakes, 2008. http://www.stakes. fi/verkkojulkaisut/tyopaperit/T3-2008-VERKKO.pdf. Accessed December 1, 2011
50. Hus Palveluhinnasto 2011. Osa 1, Tuotteistetut sairaanhoidolliset palvelut; Osa 2 Suoriteperusteiset sairaanhoidolliset palvelut. Helsinki: Helsingin Ja Uudenmaan Sairaanhoitopiiri (Hospital District of Helskinki and UUsimaa), http://www.hus.fi/default.asppath1,28,820,823,3018. Accessed December 1, 2011
51. Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105.
52. Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham, 1998
53. Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004;71:155-75
54. Oh PI, Lanctô t KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56 (Pubitemid 34094047)
55. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8 (Pubitemid 26194509)
56. ATC/DDD index 2012. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc-ddd-index/. Accessed December 2, 2012
57. The World Fact Book: Finland. https://www.cia.gov/library/publications/ theworld-factbook/geos/fi.html. Accessed December 2, 2011
58. National Institute for Health and Clinical Excellence (NICE). http://www. nice.org.uk/. Accessed December 5, 2011
59. Yahoo Finance Currency Converter. http://ca.finance.yahoo.com/currencies/ converter/#fromGBP;toEUR;amt1. Accessed December 4, 2011
60. Koskinen H, Martikainen JE, Maljanen T. Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005. Clin Ther 2009;31:1469-77
61. Niskanen P, Pihkanen TA. A comparative study of home treatment and hospital care in the treatment of schizophrenic and paranoid psychotic patients. Acta Psychiatr Scand 1971;47:271-7
62. Einarson TR, Zilbershtein R, Vicente V, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry 2012;11:18
63. All Wales Medicines Strategy Group. Final appraisal report: Olanzapine depot (ZypAdhera-), Lilly UK. Advice No: 1510. Penarth, Wales: All Wales Medicines Strategy Group. 2010. http://www.wales.nhs.uk/sites3/Documents/371/ olanzapine%20depot%20(ZypAdhera)%20schizophrenia. pdf. Accessed October 10, 2011
64. Farahati F, Boucher M, Moulton K, et al. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Heath, 2007
65. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713-30
66. Suokas JT, Perala J, Suominen K, et al. Epidemiology of suicide attempts among persons with psychotic disorder in the general population. Schiz Res 2010;124:22-8
67. Alaraisanen A, Miettunen J, Rasanen P, et al. Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc Psychiatr Psychiatr Epidemiol 2009;44:1107-10
68. Honkonen T, Henriksson M, Koivisto AM, et al. Violent victimization in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2004;39:606-12 (Pubitemid 39369160)
69. Laajasalo T, Hakkanen H. Excessive violence and psychotic symptomatology among homicide offenders with schizophrenia. Crim Behav Ment Health 2006;16:242-53 (Pubitemid 46941055)